The Securities and Exchange C		viewed the information in this filing	and has not determined if
The re	it is accurate ar eader should not assume that the in	nd complete. nformation is accurate and complete.	
UNITED S	STATES SECURITIES AND EX Washington, D.C. 20 FORM D		OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00
	Notice of Exempt Offering	of Securities	<u> </u>
L. Issuer's Identity			
CIK (Filer ID Number)	Previous None	Entity Type	
<u>0001299130</u>	PACIFIC BIOSCIENCES	OF CALIFORNIA INC X Corporation	
Name of Issuer	NANOFLUIDICS INC	Limited Partne	ership
PACIFIC BIOSCIENCES OF CALIFO		Limited Liabili	
Jurisdiction of Incorporation/Organiz DELAWARE	allon	General Partr	
Year of Incorporation/Organization			
X Over Five Years Ago		Other (Specify	y)
Within Last Five Years (Specify	Year)		
Yet to Be Formed			
2. Principal Place of Business and	Contact Information		
Name of Issuer			
PACIFIC BIOSCIENCES OF CALIFO	RNIA, INC.		
Street Address 1	Street A	ddress 2	
1305 O'BRIEN DRIVE	te/Province/Country ZIP/Post	alCode Phone Number of	of locuor
-	LIFORNIA 94025	650-521-8000	JIISSUEI
3. Related Persons			
Last Name	First Name	Middle Name	
Botstein	David	muule Name	
Street Address 1	Street Address 2		
Pacific Biosciences of California, Inc.	1305 O'Brien Drive		
City	State/Province/Country	ZIP/PostalCode	
Menlo Park	CALIFORNIA	94025	
Relationship: Executive Officer			
Clarification of Response (if Necessa	ary):		
Last Name	First Name	Middle Name	
Ericson Street Address 1	William Street Address 2	W.	
Pacific Biosciences of California, Inc.	1305 O'Brien Drive		
City	State/Province/Country	ZIP/PostalCode	
Menlo Park	CALIFORNIA	94025	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Necessa	ary):		
Last Name	First Name	Middle Name	
Henry	Christian	0.	
Street Address 1	Street Address 2		
Pacific Biosciences of California, Inc.	1305 O'Brien Drive		
City	State/Province/Country	ZIP/PostalCode	
Menlo Park Relationship: X Executive Officer	CALIFORNIA	94025	

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Livingston	Randall	S.
Street Address 1	Street Address 2	
Pacific Biosciences of California, Inc.	1305 O'Brien Drive	
City	State/Province/Country	ZIP/PostalCode
Menlo Park	CALIFORNIA	94025
Relationship: Executive Officer X	Director Promoter	
Clarification of Response (if Necessary):	
Last Name	First Name	Middle Name
Milligan	John	F.
Street Address 1	Street Address 2	
Pacific Biosciences of California, Inc.	1305 O'Brien Drive	
City	State/Province/Country	ZIP/PostalCode
Menlo Park	CALIFORNIA	94025
Relationship: \Box Executive Officer X	Director Promoter	
Clarification of Response (if Necessary):	
Last Name	First Name	Middle Name
Mohr	Marshall	
Street Address 1	Street Address 2	
Pacific Biosciences of California, Inc.	1305 O'Brien Drive	
City	State/Province/Country	ZIP/PostalCode
Menlo Park	CALIFORNIA	94025
Relationship: Executive Officer X	Director Promoter	
Clarification of Response (if Necessary):	
Last Name	First Name	Middle Name
Ordonez	Kathy	
Street Address 1	Street Address 2	
Pacific Biosciences of California, Inc.	1305 O'Brien Drive	
City	State/Province/Country	ZIP/PostalCode
Menlo Park	CALIFORNIA	94025
Relationship: Executive Officer X		
Clarification of Response (if Necessary):	
Last Name	First Name	Middle Name
Shapiro	Lucy	
Street Address 1	Street Address 2	
Pacific Biosciences of California, Inc.	1305 O'Brien Drive	
City	State/Province/Country	ZIP/PostalCode
Menlo Park	CALIFORNIA	94025
Relationship: Executive Officer X	Director Promoter	
Clarification of Response (if Necessary):	
Last Name	First Name	Middle Name
Valantine	Hannah	A.
Street Address 1	Street Address 2	
Pacific Biosciences of California, Inc.	1305 O'Brien Drive	
City	State/Province/Country	ZIP/PostalCode
Menlo Park	CALIFORNIA	94025
Relationship: Executive Officer X	_	
Clarification of Response (if Necessary).	

Kim Street Address 1 Pacific Biosciences of California, Inc. City Menlo Park Relationship: X Executive Officer Dir Clarification of Response (if Necessary):	Susan Street Address 2 1305 O'Brien Drive State/Province/Country CALIFORNIA ector Promoter	G. ZIP/PostalCode 94025
Last Name Van Oene Street Address 1 Pacific Biosciences of California, Inc. City Menlo Park Relationship: X Executive Officer Dir Clarification of Response (if Necessary):	First Name Mark Street Address 2 1305 O'Brien Drive State/Province/Country CALIFORNIA ector Promoter	Middle Name ZIP/PostalCode 94025
Last Name Eidel Street Address 1 Pacific Biosciences of California, Inc. City Menlo Park Relationship: X Executive Officer Dir Clarification of Response (if Necessary):	First Name Jeff Street Address 2 1305 O'Brien Drive State/Province/Country CALIFORNIA ector Promoter	Middle Name ZIP/PostalCode 94025
4. Industry Group Agriculture Banking & Financial Services Commercial Banking Insurance Investing Pooled Investment Fund Is the issuer registered as an investment Company under the Investment Company under the Investment Company Act of 1940? Yes No Other Banking & Financial Services Energy Coal Mining Electric Utilities Energy Conservation Oil & Gas Other Energy Other Energy Other Energy	Residential	Retailing Restaurants Technology Computers Telecommunications X Other Technology Travel Airlines & Airports Lodging & Conventions Tourism & Travel Services Other Travel Other Travel Other Travel
Revenue Range OR No Revenues \$1,000,000 \$1,000,001 - \$5,000,000 \$1,000,001	Aggregate Net Asset Va No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,00	sset Value

φ <u>1</u> ,000,00	
000,001 - \$	5,000,000

\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000
X Over \$100,000,000	Over \$100,000,000
Decline to Disclose	Decline to Disclose
Not Applicable	Not Applicable
6. Federal Exemption(s) and Exclusion(s) Claime	ed (select all that apply)
	Investment Company Act Section 3(c)
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1) Section 3(c)(9)
Rule 504 (b)(1)(i)	Section 3(c)(2) Section 3(c)(10)
Rule 504 (b)(1)(ii)	Section 3(c)(3)
Rule 504 (b)(1)(iii)	Section 3(c)(4) Section 3(c)(12)
X Rule 506(b)	
Rule 506(c)	Section 3(c)(5)
Securities Act Section 4(a)(5)	Section 3(c)(6) Section 3(c)(14)
	Section 3(c)(7)
7 Type of Filing	
7. Type of Filing	
	First Sale Yet to Occur
Amendment	
8. Duration of Offering	
Does the Issuer intend this offering to last more that	n one year? Yes X No
9. Type(s) of Securities Offered (select all that ap	pply)
X Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Anoth	er Security Mineral Property Securities
Security to be Acquired Upon Exercise of Option	n, Warrant or Other Other (describe)
Right to Acquire Security	
10. Business Combination Transaction	
Is this offering being made in connection with a bus merger, acquisition or exchange offer?	iness combination transaction, such as a X Yes No
Clarification of Response (if Necessary):	
6,349,571 shares of Common Stock of Pacific Bioscience Biosystems, Inc.	es of California, Inc. issued on August 2, 2023 in connection with the acquisition of Apton
11. Minimum Investment	
Minimum investment accepted from any outside inv	estor \$0 USD
12. Sales Compensation	
Recipient	Recipient CRD Number X None
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None
Street Address 1	Street Address 2
City	State/Province/Country ZIP/Postal Code
State(s) of Solicitation (select all that apply) Al Check "All States" or check individual States	States Foreign/non-US
13. Offering and Sales Amounts	
Total Offering Amount \$85,000,000 USD or	Indefinite
Total Amount Sold \$85,000,000 USD	Indennie
	Indefinite

Clarification of Response (if Necessary):

Amounts shown are based on a value of \$13.11 per share (volume weighted average price of a share of Issuer's Common Stock as reported by NASDAQ for the 30 trading days ending on and including the 2nd trading day immediately prior to August 2, 2023).

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD	Estimate

Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.	/s/ Brett Atkins	Brett Atkins	General Counsel	2023-08-17

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D. States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.